On May 6th, Dr. Shan Lu gave a presentation on behalf of the HVTN124 protocol team during a plenary session that was part of the larger 2021 HVTN Full Group Meeting. He shared a summary of the excellent immunogenicity data obtained from the multi-center phase 1a study testing the investigational HIV vaccine candidate PDPHV, a polyvalent DNA/Protein HIV Vaccine. To read the whole press release, click on the link below.
